Stephens starts TransMedics with an Overweight rating, $151 price target

As previously reported, Stephens initiated coverage of TransMedics with an Overweight rating and $151 price target. TransMedics is a commercial stage medical device company marketing its Organ Care System for use in organ transplants, notes the firm, which believes the company is positioned to drive long-term growth and sustained profitability with its “well capitalized balance sheet.”